SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Read More…\n\nSCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Read More…\n\nSCYNEXIS, Inc. posted its earnings results on Wednesday, May, 14th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.14 million. SCYNEXIS had a negative net margin of 425.41% and a negative trailing twelve-month return on equity of 66.21%. When did SCYNEXIS's stock split? Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are SCYNEXIS's major shareholders? SCYNEXIS's top institutional shareholders include Tabor Asset Management LP (0.49%) and Tabor Asset Management LP (0.49%). . How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include , , , , , and .\n\nCompany Calendar Last Earnings**5/14/2025** Today**5/17/2025** Fiscal Year End**12/31/2025** Industry, Sector and Symbol Stock Exchange**** Sector**** Industry**Pharmaceutical preparations** Sub-Industry**Pharmaceutical Products** Current Symbol**NASDAQ:SCYX** CIK**** Web**** Phone**** Fax**** Employees**60** Year Founded**N/A** Profitability **($0.56)** Trailing P/E Ratio**N/A** Forward P/E Ratio**N/A** P/E Growth**N/A** **$67.04 million** **-425.41%** Pretax Margin**-422.22%** **-66.21%** **-38.84%** Debt **N/A** Sales & Book Value Annual Sales**$3.75 million** **$1.36 per share** Price / Cash Flow**0.58** **$1.96 per share** Price / Book**0.40** Miscellaneous **38,981,000** Free Float**36,867,000** **$30.79 million** Optionable**Optionable** Beta**1.65**

SCYNEXIS (SCYX) Stock Price, News & Analysis

SCYNEXIS, Inc. is a biotechnology company focused on developing medicines for drug-resistant infections. It has partnerships with major pharmaceutical firms and reported financial results, including a stock split and institutional shareholder details.